A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of continuous oral Xeloda administration in
combination with intravenous irinotecan as a first-line treatment in patients with advanced
and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months
and the target sample size is <100 individuals.